The nuclear export protein XPO1—from biology to targeted therapy

AS Azmi, MH Uddin, RM Mohammad - Nature reviews Clinical oncology, 2021 - nature.com
Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

[HTML][HTML] Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials

B Goel, AK Tiwari, RK Pandey, AP Singh, S Kumar… - Translational …, 2022 - Elsevier
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology

DG Pfister, S Spencer, D Adelstein, D Adkins… - Journal of the National …, 2020 - jnccn.org
Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment …

NCCN guidelines insights: head and neck cancers, version 1.2018

AD Colevas, SS Yom, DG Pfister, S Spencer… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment
recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary …

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after …

JPH Machiels, RI Haddad, J Fayette, LF Licitra… - The Lancet …, 2015 - thelancet.com
Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and
neck (HNSCC) progressing after first-line platinum regimens have a poor prognosis and few …

Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma

AG Sacco, EE Cohen - Journal of clinical oncology, 2015 - ascopubs.org
This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

Head and neck cancer

A Argiris, MV Karamouzis, D Raben, RL Ferris - The Lancet, 2008 - thelancet.com
Most head and neck cancers are squamous cell carcinomas that develop in the upper
aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol …

Head and neck cancer: changing epidemiology, diagnosis, and treatment

S Marur, AA Forastiere - Mayo Clinic Proceedings, 2008 - Elsevier
Head and neck cancers account for less than 5% of all cancers and for less than 3% of all
cancer deaths in the United States. The populations at risk for head and neck cancers are …

Head and neck cancers, version 2.2014

DG Pfister, S Spencer, DM Brizel, B Burtness… - Journal of the National …, 2014 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the most common …

[HTML][HTML] Optimal treatment for recurrent/metastatic head and neck cancer

JB Vermorken, P Specenier - Annals of oncology, 2010 - Elsevier
While a large proportion of patients presenting with stage I and II squamous cell carcinoma
of the head and neck (SCCHN) will remain disease free after single modality treatment, the …